{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:45:01Z","timestamp":1780490701916,"version":"3.54.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["5T32HL125247\\u201310"],"award-info":[{"award-number":["5T32HL125247\\u201310"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajpc.2026.101421","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T22:49:13Z","timestamp":1768171753000},"page":"101421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2451-3583","authenticated-orcid":false,"given":"Danh Q","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parag H","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Navar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.ajpc.2026.101421_bib0001","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Cholesterol treatment trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u2008000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"issue":"10349","key":"10.1016\/j.ajpc.2026.101421_bib0002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ajpc.2026.101421_bib0003","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ajpc.2026.101421_bib0004","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ajpc.2026.101421_bib0005","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101421_bib0006","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ajpc.2026.101421_bib0007","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0008","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101421_bib0009","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of Cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2023.8646","article-title":"Low-density lipoprotein cholesterol levels in adults with coronary artery disease in the US, January 2015 to March 2020","volume":"330","author":"Aggarwal","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2026.101421_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2024.100673","article-title":"Temporal trends and racial\/ethnic- and sex-differences in LDL cholesterol control among US adults with self-reported atherosclerotic cardiovascular disease","volume":"18","author":"Nguyen","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101421_bib0012","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322\u2005153 patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101421_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011765","article-title":"Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry","volume":"8","author":"Bradley","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jacl.2022.10.009","article-title":"Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic","volume":"17","author":"Chiou","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","article-title":"Real-world utilization of bempedoic acid in an academic preventive cardiology practice","volume":"16","author":"Warden","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2020.11.004","article-title":"PCSK9 inhibition in clinical practice: treatment patterns and attainment of lipid goals in a large health maintenance organization","volume":"15","author":"Zafrir","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.ajpc.2026.101421_bib0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ahj.2019.05.009","article-title":"Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: results from the patient and provider assessment of lipid management (PALM) registry","volume":"214","author":"Nanna","year":"2019","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ajpc.2026.101421_bib0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1358863X18758914","article-title":"Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the department of veterans affairs","volume":"23","author":"McBride","year":"2018","journal-title":"Vasc Med"},{"issue":"4","key":"10.1016\/j.ajpc.2026.101421_bib0019","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/jech.2004.029454","article-title":"A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena","volume":"60","author":"Merlo","year":"2006","journal-title":"J Epidemiol Comm Health"},{"key":"10.1016\/j.ajpc.2026.101421_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100177","volume":"6","author":"Baum","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101421_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007237","article-title":"Predictors of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) inhibitor prescriptions for secondary prevention of clinical atherosclerotic cardiovascular disease","volume":"14","author":"Blumenthal","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101421_bib0022","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jacl.2021.08.001","article-title":"Race\/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction","volume":"15","author":"Colvin","year":"2021","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101421_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2023.100669","article-title":"Sex differences in cardiovascular outcomes and cholesterol-lowering efficacy of PCSK9 inhibitors: systematic review and meta-analysis","volume":"2","author":"Rivera","year":"2023","journal-title":"JACC Adv"},{"issue":"12","key":"10.1016\/j.ajpc.2026.101421_bib0024","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jacc.2021.07.022","article-title":"Side effect patterns in a crossover trial of statin, Placebo, and No treatment","volume":"78","author":"Howard","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2026.101421_bib0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2024.06.012","article-title":"Achievement of LDL-C <55 mg\/dL among US adults: findings from the cvMOBIUS2 registry","volume":"279","author":"Navar","year":"2025","journal-title":"Am Heart J"},{"issue":"25","key":"10.1016\/j.ajpc.2026.101421_bib0026","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ajpc.2026.101421_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.040768","article-title":"Prescriber uptake and use of novel lipid-lowering therapies","volume":"14","author":"Hwang","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ajpc.2026.101421_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100940","article-title":"Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy","volume":"21","author":"Hwang","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12913-018-2863-x","article-title":"Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain","volume":"18","author":"Etxeberria","year":"2018","journal-title":"BMC Health v Res"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0030","first-page":"87","article-title":"Effect of a computer-guided, quality improvement program for cardiovascular disease risk management in primary health care","volume":"8","author":"Peiris","year":"2015","journal-title":"Circ: Cardiovasc Qual Outcomes"},{"issue":"1","key":"10.1016\/j.ajpc.2026.101421_bib0031","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamacardio.2022.4373","article-title":"Effect of nudges to clinicians, patients, or both to increase statin prescribing","volume":"8","author":"Adusumalli","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.ajpc.2026.101421_bib0032","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamacardio.2017.3451","article-title":"Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy","volume":"2","author":"Navar","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.ajpc.2026.101421_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005910","article-title":"PCSK9 Inhibitors prior authorization","volume":"12","author":"Nasir","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.1016\/j.ajpc.2026.101421_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.21993","article-title":"Stroke risk reduction in atrial fibrillation through pharmacist prescribing","volume":"7","author":"Sandhu","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ajpc.2026.101421_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamacardio.2025.0244","article-title":"Encouraging pharmacist referrals for evidence-based statin initiation","volume":"10","author":"Fanaroff","year":"2025","journal-title":"JAMA Cardiol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726000152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667726000152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:39:51Z","timestamp":1779694791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667726000152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S2666667726000152"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101421","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinician-level variation in lipid management for secondary prevention of atherosclerotic cardiovascular disease: Opportunities for practice improvement","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2026.101421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101421"}}